The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in
Problems at a contract manufacturing organisation have scuppered Eli Lilly’s hopes of a timely FDA approval for lebrikizumab, its IL-13 inhibitor for the treatment of atop
Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea
Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable
Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA has approved Leo Pharma's rival antibody tralokinumab.
Eli Lilly had a lot riding on its two phase 3 trials of IL-13 inhibitor lebrikizumab in atopic dermatitis (AD) – and it now looks like it has backed a winner.